10 results
For women with a singleton fetus in breech presentation at term, this study answers the question if atosiban is more effective compared to fenoterol as a tocolyticum in external cephalic version
To compare the effectiveness of the tocolytic agents Nifedipine (a calcium channel blocking agent) versus Atosiban (an oxytocin receptor antagonist) in the improvement of neonatal outcome in women with threatened preterm labour (25-34 weeks…
To investigate the potential of atosiban as a treatment for pain caused by endometriosis.
To evaluate in a feasibility study whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
The purpose of this study is to establish efficacy and safety of ligelizumab (QGE031) versus placebo in participants with chronic inducible urticaria who remain symptomatic despite treatment with H1 antihistamine.
The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.
The purpose of the study is to establish the efficacy and safety of ligelizumab in treating adult and adolescent subjects with chronic spontaneous urticaria. This study also looks how:• further treatment of ligelizumab works following ligelizumab or…
The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30 to 34 weeks) is (cost-) effective compared with placebo in improving neonatal morbidity and mortality.
The purpose of this Phase 3 study is to evaluate the safety and clinical efficacy of ligelizumab 240 mg and 120 mg given subcutaneously (s.c.) every 4 weeks (q4w) to ensure protection against allergic reaction by decreasing the sensitivity to oral…
The primary objective is to investigate the efficacy of VR, complementary to standard care, in reducing intensity of pain in SCD patients hospitalized with VOC compared to the efficacy of another distraction method (tablet use) next to standard care…